Transplantation of Microbes for Treatment of Metabolic Syndrome & NAFLD

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

April 30, 2018

Study Completion Date

December 31, 2018

Conditions
Diabetes MellitusNon-alcoholic Fatty Liver Disease
Interventions
BIOLOGICAL

Autologous

Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from the patient prior to colonic preparation.

BIOLOGICAL

Allogeneic

Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from a lean donor prior to colonic preparation.

Trial Locations (1)

N6A 4V2

Michael Silverman, London

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT02496390 - Transplantation of Microbes for Treatment of Metabolic Syndrome & NAFLD | Biotech Hunter | Biotech Hunter